Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Hagens Berman: National Class-Action Lawsuit Accuses Sanofi of Concealing Zantac Cancer Risk

share with twitter share with LinkedIn share with facebook
share via e-mail
09/13/2019 | 09:13pm EDT

Law firm urges Zantac users to find out their rights against drug maker who knowingly sold potentially carcinogenic medication

A newly filed class-action lawsuit accuses international drug maker Sanofi of intentionally concealing risks in its popular heartburn medication, Zantac, which has been found to contain a carcinogenic chemical at 26,000 times the FDA-approved limit, according to the lawsuit filed by Hagens Berman.

If you have taken Zantac, you may have ingested carcinogens. Find out your rights »

The lawsuit, filed Sept. 13, 2019, in the U.S. District Court for the Northern District of California accuses Sanofi and Boehringer Ingelheim of knowingly manufacturing and selling over-the-counter Zantac containing a concealed carcinogen to millions of people in the U.S. suffering from heartburn and other gastrointestinal issues, including sour stomach, acid reflux or gastroesophageal reflux disease (GERD).

According to the complaint, Zantac contains the active ingredient ranitidine. When ingested, ranitidine metabolizes into N-nitrosodimethylamine (NDMA) which the FDA, EPA and World Health Organization (WHO) classify as a carcinogen.

The FDA has established a permissible daily intake limit of 96ng of NDMA, but recent testing using FDA-approved methods detected more than 2,500,000ng of NDMA per 150mg tablet of Zantac. Each Zantac tablet has been found to contain 26,000 times the FDA-approved amount of NDMA that can be safely ingested daily.

“Millions of people in the U.S. suffer from heartburn, and for years, Zantac has been sold to the masses as a safe and easy-to-find remedy for that common ailment," said Steve Berman, managing partner of Hagens Berman and attorney leading the case for consumers. “We’re certain that if those millions of consumers knew that the Zantac they take contains known carcinogens, they would be rightfully outraged.”

“Sanofi knew that Zantac contains a carcinogen, yet it chose to conceal these risks to the public to line its own pockets,” Berman added.

Zantac was the first drug to total $1 billion in sales.

According to the lawsuit, “Zantac’s unprecedented sales were possible only because of a deception perpetrated by the drug’s manufacturers on consumers…”

What Big Pharma Knew About Zantac’s Carcinogenic Risks

The dangers of NDMA have been publicly known for more than 40 years, according to the lawsuit, and the WHO has described NDMA as “clearly carcinogenic.” NDMA itself belongs to a family of chemicals called N-nitrosamines, which the EPA refers to as “potent carcinogens.”

During the period that Sanofi and Boehringer manufactured and sold Zantac, numerous scientific studies were published showing, among other things, that ranitidine forms NDMA when placed in drinking water, and that a person who consumes the drug has a 400‑fold increase of NDMA concentration in their urine, according to the lawsuit.

Attorneys say that despite the accumulating scientific evidence showing Zantac exposed users to extremely high levels of NDMA, neither Sanofi nor Boehringer disclosed this risk.

“Had Defendants disclosed that Zantac results in unsafe levels of NDMA in the human body, no person, let alone a reasonable person, would have purchased and consumed Zantac,” the complaint states.

The lawsuit seeks to represent anyone who purchased over-the-counter Zantac between Jan. 1, 2010 and the present. Attorneys hope to secure repayment for those who purchased the drug, as well as a permanent injunction from the court under the Legal Remedies Act requiring the drug makers to either cease selling Zantac or add a warning to the label.

The suit accuses Sanofi and Boehringer of violating state consumer-protection laws in its failure to disclose the harmful levels of NDMA in Zantac.

Both the U.S. FDA and European Commission recently announced that they are also investigating Zantac and ranitidine for NDMA.

If you have concerns about any potential adverse health risks associated with Zantac (or generic ranitidine consumption), Hagens Berman recommends that you discuss the allegations in this lawsuit with your physician.

Find out more about the class-action lawsuit against Sanofi for cancer-causing compounds in Zantac.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is a consumer-rights class-action law firm with nine offices across the country. The firm’s tenacious drive for plaintiffs’ rights has earned it numerous national accolades, awards and titles of “Most Feared Plaintiff’s Firm,” and MVPs and Trailblazers of class-action law. More about the law firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
09/13HAGENS BERMAN : National Class-Action Lawsuit Accuses Sanofi of Concealing Zanta..
09/13SANOFI : FDA Finds Probable Carcinogen in Some Versions of Zantac --Update
09/13SANOFI : FDA Finds Probable Carcinogen in Some Versions of Zantac --Update
09/13SANOFI : FDA Finds Probable Carcinogen in Some Versions of Zantac
09/13DISCOVER FINANCIAL SERVICES : Names Greene as Financial Chief
09/11SANOFI : India Plans to Sell Pharmaceutical Manufacturing Site in India to Zenti..
09/10LEXICON PHARMACEUTICALS : Sanofi to pay Lexicon $260 million for terminated part..
09/10LEXICON PHARMACEUTICALS : Says It Terminated Sanofi Alliance
08/30Novartis takes aim at Roche's star MS drug
08/29United States Over The Counter Drugs Market Analysis Potential Growth, Demand..
More news
Financials (EUR)
Sales 2019 36 254 M
EBIT 2019 9 474 M
Net income 2019 4 196 M
Debt 2019 14 641 M
Yield 2019 3,96%
P/E ratio 2019 25,5x
P/E ratio 2020 16,8x
EV / Sales2019 3,15x
EV / Sales2020 2,97x
Capitalization 99 582 M
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 24
Average target price 88,57  €
Last Close Price 79,53  €
Spread / Highest target 25,7%
Spread / Average Target 11,4%
Spread / Lowest Target -0,67%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI5.12%110 279
JOHNSON & JOHNSON1.07%345 150
ROCHE HOLDING LTD.10.52%236 116
PFIZER-15.44%204 151
NOVARTIS18.45%200 777